相关实验视频

Updated: Jun 28, 2025

Genome Engineering of Primary Human B Cells Using CRISPR/Cas9

Genome Engineering of Primary Human B Cells Using CRISPR/Cas9

Published on: November 3, 2020

在B细胞淋巴瘤中使用CRISPR/Cas9基因编辑的应用和进展:叙述性综述

Ying Jin¹, Haiyi Wu¹, Jianzhao Liu²

¹Department of Hematology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.

Translational cancer research

|April 15, 2024

概括

集群定期间隔的短平行列重复 (CRISPR) /与CRISPR相关的9 (Cas9) 基因编辑显示了B细胞淋巴瘤治疗的前景. 本综述探讨了改善患者预后和治疗疗效的潜在目标.

科学领域:

生物技术是生物技术.
遗传学遗传学是一个
在瘤学瘤学.

背景情况:

由于个体特异性和耐药性,B细胞淋巴瘤的治疗面临着挑战.
化疗和生物疗法是标准的治疗方法,但疗效不同.
基因编辑CRISPR/Cas9提供了新的治疗潜力.

研究的目的:

探索使用CRISPR/Cas9.9增强B细胞淋巴瘤治疗的潜在目标.
优化治疗计划,改善患者的预后.
审查CRISPR/Cas9在B细胞淋巴瘤中的当前应用和进展.

主要方法:

对最新文献进行全面的叙事审查.
研究CRISPR/Cas9基因编辑概念和选图书馆程序.
专注于CRISPR/Cas9应用和B细胞淋巴瘤的进展.

主要成果:

CRISPR/Cas9技术是一个快速发展的领域,具有显著的应用价值.
确定了候选基因,信号通路和细胞因子作为潜在的治疗点.
突出了CRISPR/Cas9在理解B细胞淋巴瘤进展中的作用.

结论:

CRISPR/Cas9基因编辑对B细胞淋巴瘤治疗有很大的前景.
通过审查关键的基因,途径和细胞因子,提供理论基础.
旨在改善临床治疗策略和患者的治疗结果.

关键词:

在B细胞淋巴瘤.这是一个CRISPR屏幕.集群定期间隔的短时间的平行体重复 (CRISPR)基因编辑基因编辑

更多相关视频

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Published on: January 5, 2018

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

相关概念视频

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...

CRISPR and crRNAs

CRISPR and crRNAs

Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...

Homologous Recombination

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...